ライフサイエンスコーパス: years or older

1 Patients age 13 years or older with an HLA-matched sibling donor or age 12 ye

2 Posaconazole may also be used in those age 13 years or older.

3 People living with HIV aged 15 years or older who initiated ART at a programme site were eli

4 Individuals aged 15 years or older who were not previously identified as HIV-posi

5 ticipants were mothers or female primary caregivers aged 15 years or older with children aged 6-24 months at enrolment.

6 Patients aged 15 years or older with resected stage IIIB-C or IV melanoma and

7 ister DGU (TR-DGU) in Germany between 2002 and 2015 aged 16 years or older and with an Injury Severity Score (ISS) of >=

8 UK Major Trauma Network that included 1548 patients aged 16 years or older who underwent surgery for a lower limb fractur

9 emiology, hospital course, and outcomes of patients aged 16 years or older with confirmed COVID-19 who had ECMO support i

10 -arm, randomised superiority trial included adults (aged 16 years or older) who presented to orthopaedic departments of 3

11 Women aged 16 years or older, not already using hormonal contraception, not

12 This recommendation statement applies to adults 18 years or older, including pregnant and postpartum persons, an

13 We included patients age 18 years or older with breast, colon, or lung cancer who were pr

14 In both studies, eligible patients were aged 18 years or older and had an Eastern Cooperative Oncology Group

15 tablished relationships, fathers or male caregivers aged 18 years or older were also eligible.

16 The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group per

17 Patients with myelodysplastic syndromes were aged 18 years or older with an ECOG performance status score of 2 or

18 tudinal survival outcomes were analysed in patients aged 18 years or older with biopsy-confirmed pancreatic cancer of any

19 Women aged 18 years or older with completely excised non-low-risk ductal ca

20 m, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least on

21 Eligible participants were women aged 18 years or older with International Federation of Gynaecology a

22 ntre, phase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastatic urothelial

23 and nurse managers were excluded) and 829 patients aged 18 years or older, able to read and write Italian and hospitaliz

24 Eligible patients were aged 18 years or older, had untreated chronic lymphocytic leukaemia,

25 Most studies enrolled any adult aged 18 years or older.

26 tudy analyzed data for 171,897 women and 167,993 men age 21 years or older with health insurance in the United States who

27 When restricted to twins 30 years or older to confirm finalized education, the heritabili

28 vascular dementia, analyzing data from participants aged 40 years or older in the National Health Insurance Database, col

29 as a proxy, whereby breast cancer cases or deaths at age 50 years or older were regarded as postmenopausal.

30 , AND PARTICIPANTS: There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-

31 Subjects aged 50 years or older were identified from the Chinese American Eye

32 Patients were eligible if they were aged 50 years or older, had been taking acid-suppressants for symptom

33 cinoma might be cost-effective for non-White individuals 50 years or older.

34 Patients age 60 years or older without previous systemic treatment for progre

35 ption in the first-line treatment of STS in patients age 60 years or older.

36 ded end-point clinical trial including 160 patients aged 60 years or older with permanent atrial fibrillation (defined as

37 Eligible patients were 60 years or older, already receiving allopurinol, and had at lea

38 lymphoma were eligible for study enrolment if they were 60 years or older, or younger than 60 years but considered unsui

39 ecommendation applies to community-dwelling older adults 65 years or older, without recognized signs or symptoms of cogni

40 e (SHARE) and included non-institutionalized adults aged 65 years or older (mean age 74 years, 59% females) endorsing at

41 Individuals aged 65 years or older and without dementia at baseline were selected

42 ective cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischemic stroke wit

43 nited Kingdom and included 2600 randomized patients aged 65 years or older with vasodilatory hypotension (assessed by tre

44 Among Medicare fee-for-service beneficiaries aged 65 years or older, dually enrolled beneficiaries had higher annu

45 nce of therapy-related acute myeloid leukaemia, or being 65 years or older.

46 We identified 60,926 retired blood donors age 70 years or older in the rosters of three region-wide Danish blo

47 <5% of those younger than 20 years to >66% of those aged 70 years or older).

48 3006 persons aged 75 years or older who were hospitalized with AMI and discharged

49 troponin concentration on the survival of patients aged 80 years or older with NSTEMI.

50 years to 304.9 deaths per 1000 cases among patients aged 85 years or older in the US.